TXNIP Promotes Human NK Cell Development but Is Dispensable for NK Cell Functionality.
NK cell development
TXNIP
human natural killer (NK) cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Sep 2022
26 Sep 2022
Historique:
received:
04
08
2022
revised:
13
09
2022
accepted:
22
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
The ability of natural killer (NK) cells to kill tumor cells without prior sensitization makes them a rising player in immunotherapy. Increased understanding of the development and functioning of NK cells will improve their clinical utilization. As opposed to murine NK cell development, human NK cell development is still less understood. Here, we studied the role of thioredoxin-interacting protein (TXNIP) in human NK cell differentiation by stable TXNIP knockdown or overexpression in cord blood hematopoietic stem cells, followed by in vitro NK cell differentiation. TXNIP overexpression only had marginal effects, indicating that endogenous TXNIP levels are sufficient in this process. TXNIP knockdown, however, reduced proliferation of early differentiation stages and greatly decreased NK cell numbers. Transcriptome analysis and experimental confirmation showed that reduced protein synthesis upon TXNIP knockdown likely caused this low proliferation. Contrary to its profound effects on the early differentiation stages, TXNIP knockdown led to limited alterations in NK cell phenotype, and it had no effect on NK cell cytotoxicity or cytokine production. Thus, TXNIP promotes human NK cell differentiation by affecting protein synthesis and proliferation of early NK cell differentiation stages, but it is redundant for functional NK cell maturation.
Identifiants
pubmed: 36232644
pii: ijms231911345
doi: 10.3390/ijms231911345
pmc: PMC9570291
pii:
doi:
Substances chimiques
Carrier Proteins
0
Cytokines
0
TXNIP protein, human
0
Txnip protein, mouse
0
Thioredoxins
52500-60-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Research Foundation - Flanders
ID : G.0444.17N; 1S29317N; 1S45317N
Références
Front Immunol. 2018 Aug 13;9:1869
pubmed: 30150991
Front Oncol. 2020 Oct 21;10:568574
pubmed: 33194655
Aging (Albany NY). 2019 Apr 26;11(8):2512-2540
pubmed: 31026227
Trends Immunol. 2013 Dec;34(12):573-82
pubmed: 24055329
Methods Mol Biol. 2010;612:15-26
pubmed: 20033631
J Hematol Oncol. 2021 Jan 6;14(1):7
pubmed: 33407739
Hum Gene Ther. 1996 Aug 1;7(12):1405-13
pubmed: 8844199
Int J Mol Sci. 2020 Dec 14;21(24):
pubmed: 33327533
J Cancer Res Clin Oncol. 2015 Mar;141(3):397-405
pubmed: 25238703
Cancer Res. 2005 May 15;65(10):3980-5
pubmed: 15899785
Open Biol. 2014 Feb 12;4:130217
pubmed: 24522884
Mol Cell Biol. 1999 Jan;19(1):612-22
pubmed: 9858585
Immunity. 2005 Feb;22(2):195-208
pubmed: 15723808
Cancers (Basel). 2020 Jun 16;12(6):
pubmed: 32560225
Nat Commun. 2021 Sep 14;12(1):5446
pubmed: 34521844
Exp Hematol Oncol. 2017 Jun 29;6:19
pubmed: 28670501
Nat Immunol. 2021 May;22(5):627-638
pubmed: 33859404
JCI Insight. 2017 Mar 9;2(5):e90063
pubmed: 28289707
Genome Biol. 2014;15(12):550
pubmed: 25516281
Exp Hematol. 2020 Apr;84:29-44
pubmed: 32259549
Front Immunol. 2017 Aug 04;8:930
pubmed: 28824650
Nat Rev Drug Discov. 2020 Mar;19(3):200-218
pubmed: 31907401
Eur J Immunol. 2014 Jul;44(7):2074-84
pubmed: 24752800
Biol Chem. 2020 Oct 25;401(11):1215-1231
pubmed: 32845855
Int J Cancer. 2020 Dec 1;147(11):2988-2995
pubmed: 32406095
Front Immunol. 2017 Feb 15;8:130
pubmed: 28261203
Blood. 2008 Aug 1;112(3):461-9
pubmed: 18650461
J Exp Med. 2006 Apr 17;203(4):1033-43
pubmed: 16606675
Biochem Soc Trans. 2021 Jun 30;49(3):1443-1456
pubmed: 34100887
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Front Immunol. 2017 Mar 27;8:360
pubmed: 28396671
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Biochim Biophys Acta. 1994 Sep 13;1219(1):26-32
pubmed: 8086474
Front Immunol. 2022 Feb 15;13:825979
pubmed: 35242135
J Biol Chem. 2010 Feb 5;285(6):3997-4005
pubmed: 19959470
Curr Opin Immunol. 2016 Apr;39:82-9
pubmed: 26845614
Semin Immunol. 2014 Apr;26(2):132-7
pubmed: 24661538
J Cell Biol. 2018 Dec 3;217(12):4141-4154
pubmed: 30348748
Neoplasma. 2016;63(5):705-16
pubmed: 27468874
EMBO J. 2007 Sep 5;26(17):3968-80
pubmed: 17690688
Mol Cell. 2013 Mar 28;49(6):1167-75
pubmed: 23453806
EBioMedicine. 2020 Sep;59:102975
pubmed: 32853984
Cell Metab. 2013 Jul 2;18(1):75-85
pubmed: 23823478
Nat Immunol. 2008 May;9(5):503-10
pubmed: 18425107
Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a026104
pubmed: 26931810